期刊
CELLS
卷 9, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/cells9122601
关键词
targeted therapy; drug resistance; tolerant and persister cells; intratumor heterogeneity; cell signaling; melanoma; lung cancer; BRAF; EGFR
类别
资金
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Universite de Rouen Normandie
- Conseil Regional de Normandie
- FEDER program of the European Union
- National Cancer Institute
- Ligue contre le Cancer de Haute-Normandie
- Agence Nationale de la Recherche
- Fondation de France
- Nabatieh Municipal Council (Lebanon)
- Fondation pour la Recherche Medicale
The capacity of cancer to adapt to treatment and evolve is a major limitation for targeted therapies. While the role of new acquired mutations is well-established, recent findings indicate that resistance can also arise from subpopulations of tolerant/persister cells that survive in the presence of the treatment. Different processes contribute to the emergence of these cells, including pathway rebound through the release of negative feedback loops, transcriptional rewiring mediated by chromatin remodeling and autocrine/paracrine communication among tumor cells and within the tumor microenvironment. In this review, we discuss the non-genetic mechanisms that eventually result in cancer resistance to targeted therapies, with a special focus on those involving changes in gene expression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据